A Dispensing Clinical of Fanfilcon A Lens Against Lotrafilcon B Lens Over 1 Month Wear Per Lens
Launched by COOPERVISION, INC. · Mar 17, 2016
Trial Information
Current as of June 19, 2025
Completed
Keywords
ClinConnect Summary
This is a 45 subject, 1-month dispensing, crossover, double-masked, randomized, bilateral study comparing the test lens against the control lens. Both test and control lenses will be used in a daily wear modality for 1 month each.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- A person is eligible for inclusion in the study if he/she:
- • Is at least 17 years of age and has full legal capacity to volunteer;
- • Has read and signed an information consent letter;
- • Is willing and able to follow instructions and maintain the appointment schedule;
- • Is correctable to a visual acuity of 20/30 or better (in each eye) with their habitual correction and the assigned study lenses;
- • Is an adapted soft contact lens wearer (For the purpose of this study: Current lens wear at least 3 days per week, 8 hours each day);
- • Demonstrates an acceptable fit with the study lenses.
- Exclusion Criteria:
- A person will be excluded from the study if he/she:
- • Is participating in any concurrent clinical or research study;
- • Is a habitual wearer of lotrafilcon B or enfilcon A lenses.
- • Has any known active\* ocular disease and/or infection;
- • Has a systemic condition that in the opinion of the investigator may affect a study outcome variable;
- • Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable;
- • Has known sensitivity to the diagnostic pharmaceuticals to be used in the study;
- • Is pregnant, lactating or planning a pregnancy at the time of enrollment; (by verbal confirmation at the Screening Visit)
- • Is aphakic;
- • Has undergone refractive error surgery;
- • For the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. Mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. Neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.
About Coopervision, Inc.
CooperVision, Inc. is a global leader in the contact lens industry, dedicated to advancing the science of vision care through innovative products and clinical research. With a commitment to enhancing the quality of life for millions of wearers worldwide, the company specializes in developing a diverse range of contact lenses, including those for myopia control, astigmatism, and presbyopia. CooperVision actively engages in clinical trials to ensure the safety, efficacy, and comfort of its products, while also contributing to the broader understanding of eye health and vision correction. By fostering partnerships with healthcare professionals and researchers, CooperVision aims to drive advancements in vision care and provide exceptional solutions that meet the evolving needs of eye care practitioners and their patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Waterloo, Ontario, Canada
Patients applied
Trial Officials
Lyndon Jones
Principal Investigator
Director, Centre for Contact Lens Research
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials